🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccine guidelines, an unexpected name appears unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning coronavirus vaccines throughout the pandemic and has focused upon possible deaths after Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to unveil major changes to the childhood immunization program earlier this month, bringing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US out of alignment with much of the international standard with no evidence for improved outcomes. The planned update has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is listed to present at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to head the office this year.

A Shift at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for halting certain childhood shot schedules in the US to become more like the Danish model, a country with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – typically the purview of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

Dr. Høeg has no obvious background in drug development, regulation or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in running a large organization. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “grasp legal statutes and the science of medication creation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who headed the center have had.”

The drug center has an enormous range of responsibilities at the FDA, the former commissioner stated.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and all of those have to be managed,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership component to the job, which manages more than 5,000 personnel. “It’s a huge leadership role, if you execute it properly,” the former official added.

Official Statement and Contentious Initiatives

Regarding concerns about Høeg’s qualifications and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns stem from flawed premises”.

“Her experience is consistent with the responsibilities of her job,” the representative stated, pointing to the months Høeg spent advising the agency head on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial rapid therapy clearance system that reportedly worried her predecessors. “How are these medications being chosen for this voucher program? Who makes the decisions?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards less stringent oversight of all drugs, except for shots.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a more documented, if problematic, history, critics observe. She released a study using non-validated volunteer-provided data to determine the incidence of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the new administration encompassed revising regulations for new vaccines and discontinuing “non-essential” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has reportedly proposed excluding teenage boys from obtaining Covid vaccines.

“She is an thorough dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a extremely disingenuous, untruthful way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|